GLP-1 receptor agonists — semaglutide (the molecule in Ozempic® and Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — have become some of the most-discussed tools for PCOS-related weight gain. Here's a grounded view of what they do.
What they can do
- Reduce appetite and cravings by mimicking a gut hormone that signals fullness, making a calorie deficit far easier to sustain.
- Improve insulin sensitivity, which directly addresses a root driver of PCOS weight gain.
- Support meaningful, gradual weight loss — often 10–15%+ of body weight over months in clinical use.
- Indirectly improve some PCOS symptoms (cycle regularity, androgen-related issues) as weight and insulin improve.
What they can't do
- They are not a cure for PCOS — symptoms can return if the medication stops and habits don't carry the result.
- They don't replace nutrition and strength training; results are best when combined.
- They aren't appropriate for everyone — a licensed provider screens for contraindications.
- They aren't FDA-approved for PCOS specifically, so insurance often won't cover them for that reason.
Semaglutide vs. tirzepatide
Tirzepatide acts on two gut hormone receptors (GLP-1 and GIP) rather than one, and in head-to-head weight-loss trials it tends to produce somewhat greater results. Semaglutide is more established and may be the starting point for many. Which is right depends on your history, goals, and tolerance — a decision for your provider, not a quiz.
Side effects to expect
The most common side effects are gastrointestinal — nausea, constipation, or reflux — usually mildest when the dose is increased slowly and often fading over a few weeks. Serious side effects are uncommon but real, which is why these medications require a prescription and provider oversight.